CLAIMS

1. A method of treating FSD which method comprises administering to a patient in need of such treatment an effective amount of a compound that is an α_{1A} and/or an α_{1L} adrenergic receptor antagonist.

2. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_i in a binding assay of less than 100nM, or a pA_2 greater than 7 in a functional assay.

3. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_i in a binding assay of less than 10nM, or a pA_2 greater than 8 in a functional assay.

4. A method of claim 1, wherein the α_{1A} and/or an α_{1L} adrenergic receptor antagonist has a K_i in a binding assay of less than 1nM, or a pA_2 greater than 9 in a functional assay.

5. A method of claim 1, wherein the compound is a selective α_{1L} and/or a selective α_{1A} adrenergic receptor antagonist.

6. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1B} receptor.

7. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1D} receptor.

8. A method of claim 5, wherein the compound is more than 10-fold selective for α_{1L} and/or α_{1A} receptor over α_{1D} and α_{1B} receptors.

9. A method of claim 1, wherein FSD is FSAD and/or FOD.

10. A method of claim 1, wherein the compound is a compound of formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 represents C_{1-4} alkyl;

R^2 represents C_{3-6} cycloalkyl;

R^3 represents a bicyclic group of the formula



wherein X and Y are selected from C and N, provided that at least one is C;

Ring A together with X and Y represents a 5- or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring;

Z is selected from H, and LR^4;

L represents a direct link, C_{1-4} alkylene or C_{1-4} alkoxyalkylene;

R^4 represents H, NR^5R^6, C_{3-6} cycloalkyl, OR^7 or Het^1;

R^5 and R^6 are independently selected from H, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with OR^8;

R^7 is selected from H, C_{1-4} alkyl, C_{1-4} alkoxyalkyl, C_{3-6}cycloalkyl, Het^2 and C_{1-4}alkyl-Het^3;

R^8 is H or C_{1-4} alkyl;

Het^1, Het^2 and Het^3 independently represent a 4 to 7 membered saturated heterocyclic group which may be mono- or bi-cyclic and which contains one or more heteroatoms selected from N, O or S, optionally substituted with OR^9 and/or C_{1-4} alkyl optionally substituted by OR^9;

R^9 is H or C_{1-4} alkyl.

11. A method of claim 10, wherein the compound is selected from:

5-cyclopropyl-7-methoxy-2-(2-([dimethylamino]methyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-(1-pyrrolidinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-(4-morpholinylmethyl)-7,8-dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-([dimethylamino]methyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(1-pyrrolidinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(1-piperidinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1H)-yl)-4(3H)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-(4-morpholinylmethyl)-3,4-dihydro[2,6]naphthyridin-2(1*H*)-yl)-4(3*H*)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(5-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-3,4-dihydro[2,6]naphthyridin-2(1*H*)-yl)-4(3*H*)-quinazolinone;

5-cyclopropyl-7-methoxy-2-(2-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-7,8-dihydro[1,6]naphthyridin-6(5*H*)-yl)-4(3*H*)-quinazolinone, or pharmaceutically acceptable salts or solvates thereof.

12. A method of claim 5, wherein the compound is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt or solvent thereof.

13. A method of claim 1, wherein the compound is selected from tamsulosin, doxazosin, terazosin, alfuzosin, or silodosin.

14. An intravaginal formulation comprising a compound as defined in claim 1.

15. A formulation as claimed in claim 14, which is a cream or a gel.

16. A method of enhancing sexual function in a female which method comprises administering to a healthy female an α_{1A} and/or an α_{1L} adrenergic receptor antagonist.

17. A method of screening for compounds useful for treating FSD, which method comprises screening compounds for antagonist activity against α_{1A} and/or α_{1L} adrenergic receptor, and selecting compounds with an K_i of less than 100nM, or a pA_2 greater than 7.

18. A method of treating or preventing FSD which method comprises administration of a combination comprising one or more α_{1A} and/or an α_{1L} adrenergic receptor antagonists, and one or more of the following auxiliary agents:

(a) A PDE5 inhibitor;

(b) A neutral endopeptidase (NEP) inhibitor;

(c) A Dopamine D3 receptor agonist;

(d) A 5HT1A receptor agonist or a 5HT2C receptor agonist;

(e) Agents used for hormone replacement therapy (HRT); and

(f) Agents used in combination for HRT and additional androgen therapy.